Pentax 2004 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2004 Pentax annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 74

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74

IOL
PLANT
IN
S
INGAPORE
19
stable, and is the earnings pillar of the Health Care division, accounting for more than 80% of sales. The number of Eye
City locations, Hoya’s contact lens retail chain in Japan, totaled 111 stores as of March 31, 2004. While pursuing a program
of scrap-and-build the Company plans an aggressive increase in the number of stores to 150 locations by fiscal 2007.
The division recorded increases in both sales and earnings in fiscal 2004, the result of new store openings in careful-
ly considered locations and store development appropriate to Eye City, with attention to such points as product lineups
tailored to the type of customer common to each store, meticulous attention to customer needs, and a level of service that
differentiates Eye City from the competition.
Looking ahead, Hoya will develop its business along with growing demand for high-value-added products such as
multifocal lenses, and toric lenses for astigmatic eyes, while maintaining a balance between purchased products and Hoya-
developed products.
Hoya seeks to be the leading company in the IOL business. In the contact lens business as well, Hoya is pursuing
greater possibilities for customer satisfaction in terms of both stores and products, and is developing a business that will
contribute to the work of ophthalmologists.
Notes:
*1. CE Marking is a product certification for compliance with the relevant safety standards of the European Union (EU).
*2. Clinical trials are tests to ensure the effectiveness and safety to humans of drugs and devices that have been developed.
*3. The FDA (Food and Drug Administration) is the U.S. authority responsible for approving clinical trials and reviews of medicines
and foods.
All production lines at the plant established in Singapore are ready for operation, and
tests are currently being conducted. This plant is expected to obtain CE Marking certifi-
cation in September 2004, and will soon begin full-scale operations to supply the
European market.
HOYA 2004-e 入稿用0705 04.7.22 8:00 PM ページ 20